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Introduction
DEK, a conserved, structurally unique DNA-modulating nucle-
ar protein, is involved in global heterochromatin integrity, tran-
scription, DNA replication, and DNA repair, and is implicated in 
gene regulation (1–3). Interestingly, DEK is secreted by activated 
human monocyte-derived macrophages and neutrophils in exo-
some and free forms (4, 5). Poly(ADP-ribosyl)ated, hyperphos-
phorylated DEK is released from T lymphocytes by Fas ligand or 
stress-mediated apoptosis (6). Secreted DEK chemoattracts neu-
trophils, cytotoxic T lymphocytes, and natural killer cells through 
an unidentified receptor, and its secretion is associated with auto-
immune diseases (4, 5, 7, 8). DEK is one of two known nuclear 
proteins that can be secreted with paracrine activity. The other, 
high-mobility group box 1 (HMGB1) protein, is secreted/released 
by macrophages under inflammatory conditions (9–11). Secreted 
DEK (a bulky, charged, and hydrophilic protein) has notably been 
shown to undergo cellular uptake and nuclear localization, medi-
ated by cell surface heparan sulfate proteoglycans (HSPGs) and 
its nuclear localization signal (NLS), respectively. Intriguingly, 
internalized DEK maintains its endogenous DNA repair and het-
erochromatin-stabilizing activities, correcting deficits otherwise 
present in cells depleted of DEK (1, 12).
We implicated endogenous nuclear DEK in regulating hema-
topoietic stem and progenitor cells (HSCs and HPCs). HPCs in 
Dek–/– mouse BM are more abundant and proliferative, coincident 
with decreased long-term competitive and secondary transplant 
repopulating capacity (1, 13, 14), suggesting that endogenous DEK 
modulates hematopoiesis. What role, if any, there is for extracel-
lular DEK in regulating hematopoiesis has not been known. Here 
we report that extracellular recombinant DEK (rDEK) greatly 
enhances ex vivo expansion of cytokine-stimulated mouse and 
human HSCs and modulates HSC and HPC numbers/function 
in vivo and in vitro, acting through chemokine receptor CXCR2 
and utilizing HSPGs as coreceptors. DEK’s ability to translocate to 
the nucleus or bind DNA did not affect hematopoietic regulation 
in vivo. Consistent with these findings, rDEK-treated mouse BM 
cells showed increased activation of several factors downstream 
of CXCR2, including ERK, protein kinase B (AKT), and p38 
MAPK. RNA-Seq analysis of rDEK-treated Dek–/– lineage-negative 
(Lin–) BM cells supported these findings that the major pathways 
activated by rDEK involved cytokine/chemokine signaling.
The nuclear protein DEK is an endogenous DNA-binding chromatin factor regulating hematopoiesis. DEK is one of only 2 
known secreted nuclear chromatin factors, but whether and how extracellular DEK regulates hematopoiesis is not known. 
We demonstrated that extracellular DEK greatly enhanced ex vivo expansion of cytokine-stimulated human and mouse 
hematopoietic stem cells (HSCs) and regulated HSC and hematopoietic progenitor cell (HPC) numbers in vivo and in vitro as 
determined both phenotypically (by flow cytometry) and functionally (through transplantation and colony formation assays). 
Recombinant DEK increased long-term HSC numbers and decreased HPC numbers through a mechanism mediated by the 
CXC chemokine receptor CXCR2 and heparan sulfate proteoglycans (HSPGs) (as determined utilizing Cxcr2–/– mice, blocking 
CXCR2 antibodies, and 3 different HSPG inhibitors) that was associated with enhanced phosphorylation of ERK1/2, AKT, and 
p38 MAPK. To determine whether extracellular DEK required nuclear function to regulate hematopoiesis, we utilized 2 mutant 
forms of DEK: one that lacked its nuclear translocation signal and one that lacked DNA-binding ability. Both altered HSC and 
HPC numbers in vivo or in vitro, suggesting the nuclear function of DEK is not required. Thus, DEK acts as a hematopoietic 
cytokine, with the potential for clinical applicability.
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Figure 2A). Increased numbers of LSK CD34+Flt3– short-term 
HSCs (ST-HSCs) (~50% increase; Figure 2B) and LSK CD34+Flt3+ 
multipotent progenitors (MPPs; ~43% increase; Figure 2C) were 
observed in Dek–/– but not WT treated mice. Thus, Dek–/– mice 
were more sensitive to exogenous DEK effects than WT mice. 
In contrast to phenotyped HSCs, absolute numbers of functional 
CFU–granulocytes, monocytes (CFU-GMs); burst-forming unit–
erythroid cells (BFU-Es); and CFU–granulocytes, erythrocytes, 
monocytes, megakaryocytes (CFU-GEMMs) per femur were 
reduced, respectively, by approximately 73%, 77%, and 68% in 
Dek–/– mice (Figure 2, D–F). A decrease in cycling HPCs was deter-
mined by a high-specific-activity tritiated thymidine (3HTdr) kill 
assay (Supplemental Figure 2, A–C). While Dek–/– mice had more 
CFU-GMs (~2.1-fold increase), BFU-Es (~2.7-fold increase), and 
CFU-GEMMs (~2.2-fold increase) when compared with WT BM at 
baseline, they had equivalent numbers when WT and Dek–/– mice 
were treated with DEK.
To control for effects of DEK preparations and to determine 
whether effects were reversible in vivo, we injected WT C57BL/6 
mice s.c. with 10 μg heat-denatured rmDEK (drmDEK), rmDEK, 
or vehicle control once a day for 2 days. BM of C57BL/6 mice 
treated with rmDEK had reduced numbers of CFU-GMs (~54% 
reduction), BFU-Es (~46% reduction), and CFU-GEMMs (~44% 
reduction) at 24 and 48 hours after final injection of DEK, which 
correlated with decreased cycling of CFU-GMs, BFU-Es, and 
CFU-GEMMs (Figure 2, G–I, and Supplemental Figure 2, D–F), 
while at 72 hours a slight reduction in DEK inhibition of HPC num-
bers and cycling (Supplemental Figure 3, A and B) was noted, with 
suppressive effects absent by 96 (Supplemental Figure 3, C and 
D) and 144 hours (Supplemental Figure 3, E and F). Thus, in vivo 
effects of rmDEK were reversible. Heat-inactivated drmDEK had 
no significant effect on colony formation (Figure 2, G–I).
To assess effects of in vivo DEK treatment on HSC function, 
we performed competitive transplantation using donor BM cells 
collected 24 or 48 hours after vehicle or rmDEK administration 
to C57BL/6 mice (CD45.1–CD45.2+). Donor CD45.1–CD45.2+ cells 
in PB of host F1 mice receiving BM isolated 24 hours after rmDEK 
treatment had decreased engraftment at all time points examined 
(Figure 2J). However, donor BM cells collected 48 hours follow-
ing DEK showed only minor decreases in engraftment 2 months 
after transplantation and no effects at later times (Figure 2K). 
This suggested that exogenous DEK resulted in time-dependent 
negative regulatory effects on engrafting HSCs. Thus, increased 
numbers of phenotypically recognizable HSCs were not reflec-
tive of their engrafting capability when rmDEK was given in vivo. 
Therefore, we examined whether BM collected from DEK-treated 
mice would show any defect in its ability to home to the host BM 
following transplantation. There was no significant change in the 
percentage of LSK CD150+, LSK, and LK cells that were CXCR4+ 
(Figure 3, A–C). However, CXCR4+ LSK CD150+, CXCR4+ LSK, 
and CXCR4+ LK cell populations demonstrated decreased 
CXCR4 levels when collected 24, but not 48, hours following 
final injection of rmDEK. This decrease in CXCR4 expression 24 
hours after in vivo DEK treatment was associated with decreased 
homing to host BM (Figure 3, D–F). When examining the BM cells 
of these same mice, we saw no change in CXCR2 levels (data 
not shown). Thus, DEK-treated mice manifested increased HSC 
Results
rDEK enhances ex vivo expansion of mouse BM and human cord blood 
HSCs. Enhancing ex vivo expansion of HSCs has the potential to 
improve the efficacy of clinical hematopoietic cell transplantation 
(HCT), especially for cord blood (CB), since HSC numbers are 
limited in single CB collections (15, 16). We assessed the effects 
of rDEK on cytokine-stimulated ex vivo expansion of mouse and 
human HSCs. Culturing mouse Lin– BM cells in expansion medi-
um containing recombinant mouse (rm) stem cell factor (rmSCF), 
rm thrombopoietin (rmTPO), and rm fms-related tyrosine kinase 
3 ligand (rmFlt3L) with rmDEK for 4 days resulted in an approxi-
mately 2.8-fold increase in long-term HSC (LT-HSC) (Lin–Sca-1+ 
c-Kit+ [LSK] CD34–CD150+CD48–CD41–) numbers (Figure 1A; n = 
6 experiments). Limiting dilution analysis compared frequencies 
of competitive repopulating units (CRU) in day 0 uncultured cells 
(input) and progeny of equivalent numbers of cells in the presence 
of rmDEK or vehicle control after 4 days in culture (Figure 1, B–F). 
DEK-cultured cells demonstrated significantly greater engraft-
ment in peripheral blood (PB) and BM compared with input and 
vehicle control cells in primary and secondary transplants (Figure 
1, B–D, and Supplemental Figure 1, A–C). Analysis of 4-month 
BM in primary transplanted mice revealed a CRU frequency of 
1:66,709 in uncultured mouse BM Lin– cells, 1:50,878 in vehicle 
control cultures, and 1:14,996 in cultures with rmDEK (Figure 1, E 
and F, and Supplemental Table 1, A and B). Thus, DEK resulted in 
an approximately 4.5-fold increase in CRU compared with that in 
input cells and an approximately 3.4-fold increase compared with 
that in vehicle-cultured cells (Figure 1F).
DEK was also evaluated for effects on human CD34+ CB 
cells cultured 4 days with recombinant human (rh) SCF (rhSCF), 
rhTPO, and rhFlt3L with 50 nM rhDEK or vehicle control. 
DEK induced an approximately 2.5-fold increase in HSC (Lin–
CD34+CD38–CD45RA–CD90+CD49f+) expansion (Figure 1G; n 
= 6 experiments). Human SCID-repopulating cells (SRCs) were 
assessed on day 0 (input), and progeny of an equivalent number 
of cells in the presence of DEK or vehicle control assessed after 
4 days (Figure 1, H–L). rhDEK-cultured cells showed significant-
ly greater engraftment in PB and BM compared with input cells 
in primary and secondary transplants (Figure 1, H–J, and Supple-
mental Figure 1, D–F). Analysis of 4-month BM revealed an SRC 
frequency of 1:5612 in uncultured cells, 1:10,990 in vehicle control 
cultures, and 1:1327 in cultures containing DEK (Figure 1, K and L, 
and Supplemental Table 1, C and D). Thus, rhDEK resulted in an 
approximately 4.2 fold increase in SRC compared with input cells 
and an approximately 8.3-fold increase compared with vehicle 
control (Figure 1L). Extracellular DEK thus significantly enhanced 
cytokine-stimulated ex vivo expansion of functional engrafting 
mouse and human HSCs.
Exogenous rmDEK alters in vivo hematopoiesis. A role for secret-
ed extracellular DEK in regulating hematopoiesis in vivo has not 
to our knowledge previously been characterized. Since C57BL/6 
BM HSCs and HPCs have endogenous nuclear DEK, we exam-
ined the effects of rmDEK on hematopoiesis in Dek–/– and WT 
littermate mice. Ten micrograms of rmDEK or vehicle control 
was injected s.c. into mice once a day for 2 days, and BM was har-
vested 48 hours later. rmDEK significantly increased numbers of 
LSK CD34–Flt3– LT-HSCs in WT (~46%) and Dek–/– mice (~84%; 
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administered DEK that have not 
yet been elucidated.
DEK effects are dependent on 
CXCR2 and Gαi protein signaling. 
DEK has a Glu-Leu-Arg (ELR) 
motif (5), similar to CXC chemo-
kines such as IL-8 (CXCL8) 
and macrophage inflammatory 
protein 2 (MIP2; CXCL2) (17). 
Like DEK, IL-8 and MIP2 sup-
press HPC proliferation (18–20). 
Dek–/– HPCs were more sensi-
tive to rmDEK inhibition than 
WT HPCs (Figure 4A), and were 
more sensitive to rhIL-8 (Figure 
4B) and rmMIP2 (Figure 4C). 
Two single-stranded DNA-tar-
geting aptamers, DTA-64 and 
DTA-85+ends, that bind tightly to 
rmDEK, but not a control aptam-
er library (8), neutralized inhibi-
tion by rmDEK but not by rhIL-8, 
rmMIP2, or CC chemokine MIP1α 
(CCL3; Figure 4D), demonstrat-
ing specificity of DEK action.
CXCR2 is a negatively acting 
receptor regulating HPC pro-
liferation and IL-8– and MIP2- 
mediated suppression of hema-
topoiesis in vitro and in vivo (21, 
22). Since DEK contains an ELR 
motif and, like ELR-containing 
chemokines, negatively regu-
lates HPC numbers, we hypothe-
sized that CXCR2 is a candidate 
receptor for extracellular DEK. 
C57BL/6 BM cells were pretreat-
ed in vitro with rat IgG (isotype 
control) or neutralizing antibod-
ies against CXCR2 or CXCR4 (a 
non-ELR-binding CXC chemo-
kine receptor that binds CXCL12) 
prior to being placed in a growth 
factor–dependent HPC colony 
assay containing rmDEK, rhIL-8, 
rmMIP2, rmMIP1α, or vehicle 
control (Figure 4E). Blocking 
CXCR2 neutralized inhibition 
by rmDEK, rhIL-8, and rmMIP2, 
but not that by rmMIP1α (a non–
ELR motif–containing chemo-
kine thats does not bind CXCR2). 
Thus, rmDEK, like IL-8 and 
MIP2, requires CXCR2 for myelosuppression. Blocking CXCR4 
did not affect actions of rmDEK or the other chemokines. To deter-
mine whether rmDEK function requires CXCR2 in vivo, we inject-
ed 10 μg rmDEK or vehicle control s.c. once a day for 2 days into 
numbers, but with overall BM engrafting deficiencies associated, 
at least in part, with decreased CXCR4 expression and homing 
efficiency. The differences in DEK’s effect ex vivo and in vivo on 
engrafting HSCs was likely due to other in vivo effects in mice 
Figure 1. Recombinant DEK enhances ex vivo expansion of mouse Lin– BM and human CD34+ CB HSCs. (A) 
Four-day HSC expansion assays using C57BL/6 Lin– BM cells. Data represent mean ± SEM fold change from input 
LT-HSC numbers of 6 pools of 2 mice (t test). (B and C) Donor cells (CD45.2+) from A and competitor Boy/J BM cells 
were infused into F1 recipients (n = 5 mice/group). 1° , primary; 2°, secondary. Percentages of donor cells in PB were 
examined after 2 (B) and 4 (C) months. P value compares the indicated group with day 0 input. (D) Secondary 
BM transplants using mice from B and C as donors. Percentages of donor cells were examined at 4 months (n = 5 
mice/group). For B–D, 1-way ANOVA with post hoc Tukey’s multiple-comparisons test was performed. (E) Poisson 
statistical analysis from the limiting dilution analysis. Different doses of donor cells from A and competitor cells 
were infused into F1 recipients. Symbols represent the percentage of negative mice for each dose of cells. Solid 
lines indicate the best-fit linear model for each data set. Dotted lines represent 95% confidence intervals. (F) CRU 
in 1 × 106 transplanted cells calculated from E. (G) Four-day HSC expansion assays using human CD34+ CB cells. 
Data represent mean ± SEM fold change from input HSC numbers for 6 individual CBs (t test). (H and I) Donor cells 
from G were infused into NSG recipients (n = 5 mice/group). Percentage of donor human CD45+ cells in PB was 
examined after 2 (H) and 4 (I) months. P value compares indicated group with day 0 input. (J) Secondary BM trans-
plants using mice from H and I as donors. Percent donor cells were examined at 4 months. For H–J, 1-way ANOVA 
with post hoc Tukey’s multiple-comparisons test was performed. (K) Poisson statistical analysis from the limiting 
dilution analysis utilizing mice from H–I. (L) Number of SRCs in 1 × 106 transplanted cells was calculated from K.
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notyped LT-HSC numbers in vivo. As reported (22), cycling HPC 
numbers in Cxcr2–/– mice were significantly increased compared 
with those in WT mice (Figure 4, F–H, and Supplemental Figure 
4, D–F) but were unaffected by rmDEK treatment, confirming 
DEK-mediated effects through CXCR2.
Dipeptidyl peptidase 4 (DPP4), a serine protease that cleaves 
select penultimate amino acids of proteins, truncates and down-
modulates functional activities of select cytokines and chemo-
Cxcr2–/– or littermate WT control mice. BM was harvested 48 hours 
later. As shown in Figure 2A, WT mice receiving rmDEK had an 
approximately 42% increase in phenotyped LT-HSCs compared 
with vehicle-treated WT mice (Supplemental Figure 4A), with no 
changes in ST-HSCs (Supplemental Figure 4B) and MPPs (Supple-
mental Figure 4C). However, rmDEK had no effect on LT-HSC, 
ST-HSC, or MPP numbers in Cxcr2–/– mice, demonstrating that 
CXCR2 is required for the DEK-mediated enhancement of phe-
Figure 2. Administration of rmDEK regulates hematopoiesis in vivo. (A–F) Dek–/– or littermate WT control mice were injected s.c. with 10 μg dialyzed rmDEK 
or vehicle once a day for 2 days (n = 3–5 mice/group). BM was harvested 48 hours after final injection. Immunophenotyping of LT-HSCs (A), ST-HSCs (B), and 
MPPs (C) was performed using flow cytometry. Data are mean ± SEM. (D–F) HPC numbers per femur were determined by CFU assay. Data are mean ± SEM 
of individually assessed mice per group plated in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001 compared with WT vehicle control; ‡P < 0.05, ‡‡‡P < 0.001 
compared with vehicle-treated Dek–/– mice. (G–I) C57BL/6 mice were given 10 μg rmDEK, drmDEK, or vehicle control as in A–F, then BM was harvested 24 and 
48 hours after final injection. HPC numbers were determined. Data are mean ± SEM of 5 individually assessed mice per group plated in triplicate. **P < 0.01, 
***P < 0.001 compared with WT vehicle control; ‡P < 0.05, ‡‡P < 0.01, ‡‡‡P < 0.001 compared with drmDEK group. (J) Engrafting efficiency of donor C57BL/6 
BM cells collected 24 hours following final injection of vehicle or rmDEK (once a day for 2 days) in PB. Data are mean ± SEM of 8 host mice. (K) Engrafting 
efficiency of donor C57BL/6 BM cells collected 48 hours following final injection of vehicle or rmDEK (once a day for 2 days) in PB. *P < 0.05, **P < 0.01, ***P 
< 0.001 compared with vehicle-treated group at the same time point. For A–K, 1-way ANOVA with post hoc Tukey’s multiple-comparisons test was used.
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ing those working through CXCR2), requires Gαi protein signaling 
to mediate myelosuppression. This suggests that while DEK, IL-8, 
and MIP2 work through the same receptor, CXCR2, the initiation 
of intracellular signaling by DEK may be different.
DEK requires HSPGs to regulate HSC and HPC numbers. 
Charged hydrophilic DEK binds to negatively charged HSPGs 
on the surface of HeLa cells (12). To determine whether DEK- 
mediated myelosuppression requires DEK binding to HSPGs, 
we pretreated C57BL/6 BM cells with Xyl-PheNO2 (p-nitrophe-
nyl-o-β-d-xylopyranoside; disrupts proteoglycan biosynthesis) 
or heparinase III (cleaves HSPGs from the cell surface) prior to 
HPC colony assay in the presence of rmDEK or vehicle control 
(Figure 5A). DEK-mediated myelosuppression was blocked with 
Xyl-PheNO2 or heparinase III, suggesting that DEK requires 
HSPGs to mediate myelosuppression. To determine whether 
HSPGs or CXCR2 are necessary for DEK-mediated enhanced 
ex vivo expansion of mouse BM LT-HSCs, we pretreated mouse 
Lin– BM cells with heparin (blocks binding of charged molecules 
to HSPGs), neutralizing CXCR2 antibody, isotype control, or 
kines. DPP4-truncated molecules downmodulate the effec-
tiveness of their own full-length forms, effects mediated at the 
receptor level (23–25). DEK and IL-8 have DPP4 truncation sites 
(14, 25). Upon DPP4 truncation, DPP4 inactivates IL-8 (21) and 
rmDEK in vitro (Figure 4I). Interestingly, DPP4-truncated DEK 
and IL-8 counteracted the suppressive activities of their respec-
tive full-length protein, as well as the other full-length protein, as 
effectively as anti-CXCR2. This strongly suggests that DEK and 
IL-8 share the same receptor, CXCR2.
As selected myelosuppressive chemokines do not require Gαi 
protein signaling to mediate inhibitory effects (26), we examined 
whether rmDEK requires Gαi protein signaling to reduce HPC 
numbers. C57BL/6 BM cells were pretreated with pertussis tox-
in (PT), and suppression by rmDEK, rhIL-8, rmMIP2, rmMIP1α, 
and rm6Ckine was examined via HPC colony assay (Figure 4J). 
Pretreatment with PT did not block rhIL-8, rmMIP2, rmMIP1α, or 
rm6Ckine inhibition of HPC colony formation, but did interfere 
with DEK-mediated inhibition of HPC colony formation, suggest-
ing that DEK, unlike other myelosuppressive chemokines (includ-
Figure 3. In vivo rmDEK treatment 
reversibly decreases CXCR4 expres-
sion and homing capability of BM 
cells. C57BL/6 mice (CD45.1–CD45.2+) 
were injected with 10 μg dialyzed WT 
rmDEK or vehicle control s.c. once a 
day for 2 days. BM was then collected 
24 or 48 hours after final injection. 
(A–C) CXCR4 expression levels were 
examined 24 and 48 hours following 
the final DEK injection by flow cytom-
etry in the CD45.1–CD45.2+ LSK CD150+ 
(A), LSK (B), and LK (C) cell popu-
lations. (D–F) Twelve million cells 
from the mice examined in A–C were 
injected i.v. into lethally irradiated 
(950 cGy, 24 hours prior) B6×Boy/J F1 
mice (CD45.1+CD45.2+) hosts. Eighteen 
hours following injection, BM from 
host mice was collected and analyzed 
by flow cytometry for the presence of 
CD45.1–CD45.2+ LSK CD150+ (D), LSK 
(E), and LK (F) cells. In A–F, data are 
mean ± SEM of 5 mice per group; P 
value is compared with vehicle con-
trol–treated mice using 1-way ANOVA 
with post hoc Tukey’s multiple-com-
parisons test.
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vehicle control prior to ex vivo expansion. Pretreating mouse Lin– 
BM cells with heparin or neutralizing CXCR2 antibody blocked 
DEK-mediated enhancement of LT-HSC numbers (Figure 5B), 
suggesting that DEK-mediated enhancement of LT-HSCs ex vivo 
is CXCR2 and HSPG dependent.
DEK-mediated trimethylation of H3K9 in LSK cells requires 
HSPGs. Extracellular DEK is internalized and remodels chromatin, 
as indicated by increased trimethylation of H3K9 in DEK-knock-
down HeLa cells in vitro (2, 12). Previous studies on nonhema-
topoietic cells suggested that DEK mediates its function, at least 
Figure 4. Inhibition of HPC numbers by DEK is CXCR2 and Gαi dependent. (A–C) HPC CFU assays with rmDEK (A), rhIL-8 (B), or rmMIP2 (C) using either 
Dek–/– or WT BM cells. **P < 0.01, ***P < 0.001 comparing doses between WT and Dek–/– BM cells. (D) HPC CFU assay examining the effect of pretreat-
ing rmDEK, rhIL-8, rmMIP2, or rmMIP1α with DEK-targeting aptamers (DTA-64 and DTA-85+ends) or control vehicle and DTA library. (E) HPC CFU assay 
examining whether pretreatment of WT BM cells with anti-CXCR2 blocking antibody inhibits rmDEK, rhIL-8, rmMIP2, or rmMIP1α effects. Vehicle, isotype 
antibody, and anti-CXCR4 blocking antibody were used as controls. **P < 0.01 compared with control. In A–E, data are mean ± SD of triplicate plates. (F–H) 
Cxcr2–/– or WT mice were injected s.c. with 10 μg dialyzed rmDEK or vehicle once a day for 2 days. BM was harvested 48 hours after final injection. HPC 
number was determined by CFU assay. Data are mean ± SEM of 4 mice per group plated in triplicate. *P < 0.05, **P < 0.01 compared with vehicle-treated 
WT mice. (I) HPC CFU assay examining whether full-length (FL) or DPP4-truncated (T) rmDEK or IL-8 alone or mixed at a 1:1 ratio affects C57BL/6 BM col-
ony formation when pretreated with anti-CXCR2 blocking antibody or isotype control. Percent inhibition was calculated based on counts from plates with 
control media added. (J) HPC CFU colony assay using C57BL/6 BM cells that were pretreated with PT (Gai inhibitor) or vehicle control, then cultured with 
rmDEK, rhIL-8, rmMIP2, rmMIP1α, or rm6Ckine. In I and J, data are mean ± SD of triplicate plates. **P < 0.01, ***P < 0.001 compared with control. For A–J, 
1-way ANOVA with post hoc Tukey’s multiple-comparisons test was used.
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in part, through regulation of heterochromatin integrity (12). We 
explored whether extracellular DEK similarly regulated LSK cell 
function. Dek–/– and littermate WT Lin– BM cells were cultured 
for 16 hours with rmDEK or vehicle control, then LSK cells were 
assessed by imaging flow cytometry for changes in expression of 
the nuclear heterochromatin marker H3K9me3 (Figure 5C). There 
was no change in H3K9me3 expression in the nucleus of WT LSK 
cells following rmDEK treatment, as determined by comparing 
the similarity scores (calculated using IDEAS software) of cells 
stained with H3K9me3 and the nuclear dye DRAQ5 (data not 
shown), similar to previous findings that only DEK-knockdown 
HeLa cells demonstrated changes in H3K9me3 following incu-
bation with rhDEK (12). However, vehicle-treated Dek–/– LSK cells 
had approximately 52% less H3K9me3 in the nucleus compared 
with WT LSK cells (Figure 5D), and pretreatment of Dek–/– LSK 
cells with rmDEK significantly increased H3K9me3 levels.
DEK must bind to HSPGs to become internalized through an 
active process in DEK-knockdown HeLa cells (12). To determine 
whether DEK required HSPGs to be internalized, we pretreat-
ed Dek–/– Lin– BM cells with heparin (Figure 5D), which inhibited 
DEK-mediated enhancement in H3K9me3 levels in the nucleus 
of Dek–/– LSK cells. Pretreating Dek–/– Lin– BM cells with Pitstop 2, 
an endocytosis inhibitor (27), or PT also inhibited DEK-mediated 
enhancement in H3K9me3 levels in the nucleus of Dek–/– LSK cells. 
Thus, DEK-mediated changes in H3K9me3 in the nucleus of LSK 
cells requires an endocytosis event involving Gαi protein signal-
ing. Interestingly, only Dek–/– LSK cells that were actively cycling 
showed major changes in nuclear H3K9me3. Pretreating Dek–/– Lin– 
BM cells with hydroxyurea prior to culture to kill actively cycling 
cells and then adding rmDEK resulted in lower nuclear H3K9me3 
levels than treatment with vehicle control alone (Figure 5D).
Inactivation of rmDEK with the aptamers DTA-64 or 
DTA-85+ends, but not a control aptamer library, blocked DEK- 
mediated enhancement of trimethylation of H3K9 (Figure 5E). 
However, blocking CXCR2 prior to incubation with DEK had no 
effect on DEK-mediated enhancement of H3K9me3 expression 
in the nucleus of Dek–/– LSK cells (Figure 5E). Although CXCR2 is 
required to mediate DEK’s effect on hematopoiesis in vivo and in 
vitro, it is apparently not required for DEK-mediated heterochro-
matin remodeling in Dek–/– LSK cells. This suggested that the het-
erochromatin remodeling actions of DEK may not be involved in 
the cytokine-like effects of DEK in regulating hematopoiesis.
Extracellular DEK does not require translocation to the nucleus 
or binding to DNA to regulate hematopoiesis. To determine wheth-
er DEK’s nuclear functions are required to mediate rmDEK- 
mediated regulation of hematopoiesis, we utilized 2 mutant 
forms of rmDEK: DEK that lacks its nuclear translocation signal 
(rhNLS-DEK) and DEK lacking DNA-binding ability via its major 
and central DNA-binding motif (SAP-box; rhDBM-DEK). As WT 
rmDEK is His-tagged and made in baculovirus, but rhNLS-DEK 
and rhDBM-DEK are GST-tagged and made in E. coli, we included 
GST-tagged WT rhDEK as another control. As shown in Figure 5, 
C–E, WT rDEK treatment resulted in increased H3K9me3 expres-
sion in the nucleus of Dek–/– LSK cells, and unsurprisingly, rhDBM-
DEK and rhNLS-DEK did not alter H3K9me3 expression (Figure 
6A), suggesting that extracellular DEK must be able to locate to 
the nucleus and bind to DNA to mediate changes in H3K9me3 
expression. We examined whether rhDBM-DEK and rhNLS-DEK 
manifest DEK’s suppressive effects on C57BL/6 BM HPC colony 
formation (Figure 6B). As shown in Figure 4A, WT rDEK dose- 
dependently inhibited HPC colony formation, and rhDBM-DEK 
and rhNLS-DEK were as efficient as WT rmDEK, suggesting that 
extracellular DEK’s ability to locate to the nucleus and bind to 
DNA is not required for in vitro inhibition of HPC numbers. The 
nuclear function of DEK was also not required for DEK-mediated 
enhancement of mouse LT-HSC numbers following ex vivo expan-
sion (Figure 6C). Both WT rDEKs significantly enhanced mouse 
LT-HSC numbers after 4 days in culture. rhDBM-DEK (~2.1-fold 
increase) and rhNLS-DEK (~2.6-fold increase) also significantly 
enhanced LT-HSC expansion, although not nearly as effectively 
as their GST WT rhDEK counterpart (~41% and ~34% reduction, 
respectively, from WT DEK).
To determine whether mutant forms of rDEK had effects on 
regulating hematopoiesis in vivo, we injected C57BL/6 mice s.c. 
once a day for 2 days with 10 μg WT rDEK, rhDBM-DEK, rhNLS- 
DEK, or vehicle control, and analyzed BM 48 hours later. WT 
rDEK, rhDBM-DEK, and rhNLS-DEK significantly increased 
LT-HSC numbers to an equivalent extent (Figure 6D), but had no 
effect on ST-HSC (Figure 6E) or MPP numbers (Figure 6F). WT 
rDEK, rhDBM-DEK, and rhNLS-DEK were equivalent in suppres-
sion of HPC numbers (Figure 6, G–I) when given in vivo to the 
same WT mice. WT and mutant rDEKs also demonstrated equiv-
alent reductions in percent cycling HPCs (Figure 6, J–L). This sug-
gests that exogenously added DEK does not need to locate to the 
nucleus, bind DNA, or affect global heterochromatin structure to 
regulate hematopoiesis in vivo.
DEK stimulates ERK, AKT, and p38 MAPK phosphorylation in 
LSK CD150+ and myeloid-enriched progenitor cells. As extracellular 
DEK’s ability to regulate HSC and HPC numbers does not appear 
to require DEK’s nuclear functional activity (but does require 
CXCR2), we assessed whether DEK activates 4 major proteins 
downstream of CXCR2: ERK1/2, AKT, p38 MAPK, and NF-κB 
(28). Lin– BM cells from WT C57BL/6 mice were stimulated with 
rhIL-8, rmDEK, or vehicle control for 15, 30, and 60 minutes and 
16 hours, and LSK CD150+ cells and myeloid-enriched progenitor 
(Lin–Sca-1–c-Kit+ or LK) cells were analyzed by flow cytometry for 
levels of ERK1/2 pT202/pY204 (Figure 7A), AKT pS473 (Figure 
7B), or p38 MAPK pT180/pY182 (Figure 7C and Supplemental 
Figure 5). Like rhIL-8, rmDEK enhanced ERK1/2 and AKT phos-
phorylation over baseline in these cells. rmDEK achieved peak 
activation of p38 MAPK pT180/pY182 levels in the LSK CD150+ 
population after 1 hour of stimulation compared with 15 minutes 
for rhIL-8. However, p38 MAPK phosphorylation reached its peak 
in LK cells at 15 minutes following either rhIL-8 or rmDEK treat-
ment, with no observable phosphorylation of ERK1/2, AKT, or p38 
MAPK after 16 hours of rhIL-8 or rmDEK stimulation.
To determine whether NF-κB was being activated following 
rmDEK treatment, we quantified the degree of NF-κB p65 trans-
location by calculating the similarity of NF-κB p65 and nuclear dye 
DRAQ5 images analyzed by ImageStream flow cytometry. Cells 
with low similarity scores exhibited little to no correlation between 
images (corresponding with predominant cytoplasmic distribution 
of NF-κB p65; s.s. <1), whereas cells with high similarity scores 
exhibited positive correlation between the images (corresponding 
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rmSCF and rhSDF1α were still able to stimulate, as they did not 
bind to CXCR2 (Supplemental Figure 7, A–F). Thus, DEK signal-
ing through CXCR2 leads to activation of ERK1/2 and AKT in LSK 
CD150+ BM cells. Blocking HSPGs by pretreating the BM cells 
with heparin interfered with cytokine-stimulated phosphoryla-
tion of ERK1/2 and AKT (Supplemental Figure 7, A–F) suggesting 
that HSPGs play a vital role in signaling of many cytokines, not 
with predominant nuclear distribution of NF-κB p65; s.s. >1). LSK 
and LK cells from rhIL-8– (at 15 and 30 minutes) or rmDEK-treat-
ed (at 30 minutes) Lin– C57BL/6 BM cells demonstrated moderate 
NF-κB p65 nuclear translocation (s.s. >1; Supplemental Figure 6).
Neutralizing CXCR2 on C57BL/6 Lin– BM cells using anti- 
CXCR2 antibody blocked rhIL-8 and rmDEK enhancement of 
ERK1/2 and AKT phosphorylation in LSK CD150+ cells, whereas 
Figure 5. Extracellular DEK’s ability to regulate hematopoiesis requires HSPGs. (A) C57BL/6 BM cells were pretreated with Xyl-PheNO2 or heparinase III to 
neutralize HSPGs and then utilized in a CFU assay. Anti-CXCR2 antibody served as a positive control, while vehicle or isotype control served as a negative 
control. Data are mean ± SD of triplicate plates. **P < 0.01 compared with vehicle control. (B) HSC expansion assays using C57BL/6 Lin– BM cells pretreat-
ed with anti-CXCR2 blocking antibody or heparin (blocks HSPGs). Isotype antibody or vehicle control served as negative control. Number of LT-HSCs in day 
0 input and number of LT-HSCs 4 days after culture in expansion media with either vehicle control or rmDEK were determined. Three pools of 2 mice were 
utilized. Data are mean ± SEM. *P < 0.05 compared with vehicle control. (C) Representative images from Amnis ImageStream analysis of H3K9me3 in the 
nucleus of WT and vehicle- or rmDEK-treated Dek–/– LSK cells. Images were taken at ×40. Numbers in the upper left are object image numbers. Scale bars: 
10 μm. (D) ImageStream analysis of H3K9me3 in the nucleus of Dek–/– LSK cells pretreated with HSPG inhibitor (heparin), endocytosis inhibitor (Pitstop 2), 
the Gαi protein signaling inhibitor PT, or an agent that kills cycling cells (hydroxyurea [HU]), then incubated for 16 hours with either vehicle or rmDEK. (E) 
H3K9me3 expression in the nucleus of Dek–/– LSK cells pretreated with anti-CXCR2 blocking antibody, anti-CXCR4 antibody, isotype antibody, or vehicle, 
then incubated for 16 hours with either vehicle or rmDEK pretreated with vehicle, aptamer library, or DEK-targeted aptamers DTA-64 and DTA-85+ends. For 
D and E, IDEAs software was used for analysis. Data are mean ± SD of triplicate tubes. *P < 0.05, **P < 0.01 compared with percent H3K9me3 levels in the 
nucleus of the vehicle group. For A–E, 1-way ANOVA with post hoc Tukey’s multiple-comparisons test was used.
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Figure 6. Extracellular DEK does not require its nuclear function to regulate hematopoiesis. (A) Analysis of H3K9me3 levels in the nucleus of Dek–/– LSK 
cells incubated with vehicle, WT rmDEK, GST-tagged WT rhDEK (GST WT rhDEK), GST-tagged mutant DNA-binding motif rhDEK (GST rhDBM-DEK), or 
GST-tagged mutant NLS rhDEK (GST rhNLS-DEK). Data are mean ± SD of triplicate tubes. *P < 0.05 compared with percent H3K9me3 levels in the nucleus 
of the vehicle group. (B) HPC colony assay examining the effect of different doses of WT or mutant DEK. Data are mean ± SD of triplicate plates. *P < 
0.05, **P < 0.01 compared with vehicle control. (C) Number of LT-HSCs in day 0 input of C57BL/6 Lin– BM cells and number of LT-HSCs 4 days after culture 
in expansion media with vehicle or WT or mutant DEK was determined. Data are ± SEM of fold change from input LT-HSC numbers of 3 pools of 2 mice. 
*P < 0.05, **P < 0.01 compared with vehicle control; ‡P < 0.05 compared with WT rmDEK or GST WT rhDEK. (D–F) C57BL/6 mice were injected s.c. with 
vehicle or 10 μg dialyzed WT or mutant DEK once a day for 2 days. BM was harvested 48 hours after final injection, and immunophenotyping of LT-HSCs 
(D), ST-HSCs (E), and MPPs (F) was performed. Data are mean ± SEM of 6 mice per group. *P < 0.05 compared with vehicle-treated mice. (G–I) HPC number 
from the mice used in D–F was determined by CFU assay. The percentage of HPCs at the time of isolation in cycle was determined by 3HTdr assays (J–L). 
Data are mean ± SEM of 6 mice per group plated in triplicate. ***P < 0.001 compared with vehicle-treated WT mice. For A–L, 1-way ANOVA with post hoc 
Tukey’s multiple-comparisons test was used.
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To further confirm whether extracellular DEK is working 
through a cytokine/chemokine signaling pathway, we determined 
which molecular pathways were activated in DEK-treated imma-
ture cells. We transcriptionally profiled DEK-treated Lin– BM from 
age- and sex-matched Dek–/– mice exposed to rmDEK or vehicle 
control in vitro. Principal component analysis clearly separated 
just rmDEK. WT rDEKs and the DEK mutants rhDBM-DEK and 
rhNLS-DEK equivalently enhanced ERK1/2 and AKT phosphor-
ylation in LSK CD150+ cells (Supplemental Figure 7, G and H), 
demonstrating that extracellular DEK’s nuclear function at the 
time points examined played no role in the ability of DEK to stim-
ulate ERK1/2 or AKT phosphorylation.
Figure 7. DEK stimulates ERK1/2, AKT, and p38 MAPK phosphorylation in LSK CD150+ and myeloid-enriched progenitor (LK) cells. (A–C) C57BL/6 BM 
LSK CD150+ cells and LK cells were examined by flow cytometry for ERK1/2 (A), AKT (B), and p38 MAPK (C) phosphorylation 15, 30, and 60 minutes, or 16 
hours following vehicle, rhIL-8, or rmDEK treatment. *P < 0.05, **P < 0.01, and ***P < 0.001 when comparing groups with vehicle control at the same time 
point (1-way ANOVA with post hoc Tukey’s multiple-comparisons test). Data are mean ± SD of triplicate tubes. (D) Heatmap representation of the 186 
differentially expressed genes (DEGs) when comparing vehicle-treated with rmDEK-treated Lin– BM. Unsupervised hierarchical clustering was performed to 
group samples (columns) and genes (rows) by similarities in data structure. Genes listed to the right of the heatmap represent factors with known induc-
tion by signaling cascades that exhibit crosstalk with CXCR2 response, including, but not limited to, AKT signaling, MAPK signaling, and NF-κB signaling. 
(E) Ontologic assessments conducted on DEK-mediated transcriptional changes with the RNA-Enrich program. A subset of concepts from the analysis 
ranked by significance is shown.
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activity (rhDBM-DEK) were able to alter hematopoiesis in vivo and 
in vitro similarly to WT rDEK, suggesting that recombinant DEK’s 
nuclear function is not responsible for DEK-mediated regulation of 
hematopoiesis in the context of our studies. What role, if any, DEK- 
mediated heterochromatin remodeling in HSCs and HPCs may 
play remains to be determined. However, collectively our data sug-
gest that DEK exerts its effect predominantly through a CXCR2 
signaling pathway and not by mediating its nuclear function.
HSPGs play an important role in regulating chemokine func-
tion by binding to chemokines, protecting them against proteol-
ysis, and sequestering chemokines on the cell surface, allowing 
for more efficient chemokine presentation and/or ligand-receptor 
clustering/signaling and thus lowering the activation threshold 
for optimal receptor signaling (30). Our data suggest that HSPGs 
serve as a coreceptor, not just an endocytosis receptor, for DEK, 
allowing for optimal DEK-mediated CXCR2-dependent cyto-
kine regulation of hematopoiesis, as DEK-mediated regulation of 
hematopoiesis is CXCR2 dependent and DEK requires HSPGs for 
ERK1/2 and AKT phosphorylation.
A potential clinically relevant result is that extracellular DEK 
treatment greatly enhanced human and mouse HSC numbers in 
cytokine-stimulated ex vivo expansion assays, a process requiring 
CXCR2 and HSPGs. It remains unclear at present why treating 
C57BL/6 mice with rDEK in vivo resulted in increased phenotyp-
ically defined HSC numbers with decreased functional engraft-
ment, while utilizing rDEK in ex vivo expansion assays enhanced 
engraftment of these cells. However, the finding reflects decreased 
CXCR4 expression on these cells and reduced homing efficiency 
with in vivo rDEK administration. We hypothesize that when giv-
ing rmDEK in vivo we may be affecting other cell types not exam-
ined in vitro in this study. One possibility is that factors may be pro-
duced following in vivo DEK treatment that indirectly influence 
hematopoiesis, possibly by decreasing the expression of CXCR4 
and the homing capabilities of these cells. Thus, in vivo infusion 
of DEK in a clinical setting may allow for negative, rather than pos-
itive, effects on hematopoiesis, although there are ex vivo means 
to enhance expression of CXCR4 and the homing of human HSCs 
that could potentially be applied (23, 32, 33).
In summary, we now show that DEK has profound effects on 
hematopoiesis ex vivo and in vivo in its soluble form, and that 
these regulating effects are mediated by DEK not as a chromatin 
factor, but rather via its cytokine/chemokine-like activity. We have 
demonstrated for the first time to our knowledge that DEK signals 
through CXCR2, an effect crucial for its ability to modulate hema-
topoiesis in vitro, ex vivo, and in vivo. DEK is active when adminis-
tered systemically to mice. Interestingly, CXCR2 and IL-8 are two 
of the most frequently overexpressed genes in cell populations 
initiating acute myeloid leukemia (AML) and myeloid dysplas-
tic syndrome (MDS), including LT-HSCs, ST-HSCs, and myeloid 
HPCs (34–36), and high expression is associated with poor clinical 
outcomes (36). This suggests that the IL-8/CXCR2 pathway may 
be a novel therapeutic target in AML and MDS. As IL-8 mediates 
DEK secretion by macrophages and neutrophils (5) and DEK acts 
through CXCR2, it may also be a useful target for modulating 
progression of MDS and AML. This is especially so in the context 
of DPP4-mediated truncation of DEK and/or IL-8; truncation of 
each has the capacity to block the action of not only its own full-
the treatment groups (Supplemental Figure 8A). We identified 186 
genes undergoing transcriptional changes driven by DEK expo-
sure (Supplemental Figure 8B), which we visualized as a heatmap 
after unsupervised hierarchical clustering (Figure 7D). Numerous 
inflammatory cytokines were upregulated, including Tnf, Il12b, and 
Cxcl10, suggesting that DEK acts as a proinflammatory factor on 
Lin– BM cells. Further suggesting a chemokine/cytokine-like role 
for DEK was the upregulation of a family of guanylate-binding 
proteins known to accentuate interferon signaling through inter-
action with G protein–coupled receptors (GPCRs). Of note, signal-
ing crosstalk between CXCR2 (a well-characterized GPCR) and a 
number of downstream effector pathways (AKT signaling, MAPK 
signaling, NF-κB signaling) was identified from transcriptional 
profiling (Figure 7E, gene list). Furthermore, ontological assess-
ment of DEK-mediated transcriptional changes revealed enrich-
ment in innate immune system and cytokine response effectors 
(Figure 7E). Even though this analysis will not allow us to differen-
tiate HSC/HPC populations from the rest of the Lin– BM cells, our 
RNA-Seq findings support our conclusion that rmDEK is most like-
ly functioning through a cytokine/chemokine signaling pathway.
Discussion
We now demonstrate that extracellular DEK potently enhances 
cytokine-induced ex vivo expansion of mouse BM and human CB 
HSCs within 4 days. This is important, for if this is translated into 
clinical application with CB cells, it would be ideal to maximally 
enhance HSC expansion in the shortest amount of time possible 
(15). Moreover, exogenous DEK regulates hematopoiesis in vivo 
and in vitro in mice. It is striking that a protein normally found as 
a chromatin factor in the nucleus of cells can have another role as 
a soluble factor affecting hematopoiesis. To understand the mech-
anisms involved, we hypothesized that since DEK contained an 
ELR motif and acted as a chemoattractant for mature hematopoi-
etic cells (5, 8), it likely functioned through the ELR motif–binding 
CXC chemokine receptor CXCR2. Blocking the ability of extra-
cellular DEK to bind to CXCR2 with neutralizing CXCR2 anti-
body and examining the effects of DEK on HSC/HPC numbers 
in rmDEK-treated Cxcr2–/– mice demonstrated that extracellular 
DEK required CXCR2 to mediate its effects on hematopoiesis in 
vitro and in vivo. rmDEK resulted in CXCR2-dependent phos-
phorylation of ERK1/2, AKT, and p38 MAPK, 3 well-characterized 
downstream CXCR2 signaling mediators. Collectively, these data 
provide strong evidence that DEK has cytokine/chemokine-like 
functions that can be leveraged for clinical applications.
DEK requires HSPGs to mediate regulatory effects on hemato-
poiesis. HSPGs can act as ligand-induced endocytic receptors (29–
31). Extracellular DEK requires HSPGs to become internalized by 
DEK-knockdown HeLa cells; pretreating cells with heparin blocked 
DEK uptake, and cells genetically modified to alter HSPG synthe-
sis or positioning failed to take up DEK (12). DEK internalization 
by DEK-knockdown HeLa cells was associated with increased 
trimethylation of H3K9 in the nucleus, resulting in increased het-
erochromatin stability in vitro in human cells and in vivo in Droso-
phila (2, 12). We demonstrated that extracellular DEK requires 
HSPGs, endocytosis, and Gαi protein signaling, but not CXCR2, 
for its ability to affect heterochromatin in Dek–/– LSK cells. How-
ever, DEK proteins lacking NLSs (rhNLS-DEK) or DNA-binding 
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formed using a mouse lineage cell depletion kit following the manufac-
turer’s protocol (Miltenyi Biotec) using 2 sequential columns. Human 
umbilical CB was obtained from Cord:Use Cord Blood Bank (Orlando, 
Florida, USA). Upon arrival, CB was washed in PBS prior to Ficoll-
Paque PLUS (GE Healthcare Bio-Sciences AB) separation of mononu-
clear cells. The CD34+ CB cells were then isolated using a CD34 immu-
nomagnetic selection kit according to the manufacturer’s protocol 
(Miltenyi Biotec) using two sequential columns. The purity of mouse 
Lin– BM cells and human CD34+ CB cells was between 92% and 96%.
Pretreatment of BM cells with inhibitors and neutralizing agents. 
To examine the importance of Gαi protein–coupled receptor signal-
ing in DEK-mediated regulation of hematopoiesis, we incubated BM 
cells from the indicated mouse strains with 500 or 1000 ng/ml PT 
(Sigma-Aldrich; catalog P7208) for 4 hours at 37°C immediately pri-
or to utilizing them in experiments. To examine the role of HSPGs in 
DEK-mediated regulation of hematopoiesis, we utilized 3 different 
inhibitors: heparin (blocks binding of molecules to HSPGs), Xyl-Phe-
NO2 (disrupts proteoglycan biosynthesis), and heparinase III (cleaves 
HSPGs from cell surface). For heparin, BM cells were pretreated with 
5 μg/ml heparin (from porcine intestinal mucosa; Sigma-Aldrich, cat-
alog H3393) for 30 minutes at 37°C immediately prior to use in exper-
iments and then washed out. For Xyl-PheNO2, BM cells were treated 
with 100 μM Xyl-PheNO2 (EMD Millipore, catalog 487870) in culture 
media (type determined by the experiment) 16 hours at 37°C imme-
diately prior to use in experiments and then washed out. For hepari-
nase III, BM cells were treated with 0.5 mIU/ml heparinase III (from 
Flavobacterium heparinum; Sigma-Aldrich, catalog H8891) in culture 
media (type determined by the experiment) for 4 hours at 37°C imme-
diately prior to use in experiments and then washed out. To neutralize 
CXCR2 and CXCR4 on the cell surface, BM cells were incubated with 
2.5 μg/106 cells of anti–mouse CXCR2 purified rat monoclonal IgG2A 
antibody (R&D Systems, clone 242216), anti–mouse CXCR4 purified 
rat monoclonal IgG2B antibody (R&D Systems, clone 247506), or iso-
type rat IgG control (azide-free; R&D Systems, catalog 6-001-F) for 
30 minutes at room temperature immediately prior to use in exper-
iments and then washed out. To examine whether DEK required 
endocytosis to mediate H3K9 trimethylation, we utilized the clathrin- 
dependent and -independent endocytosis inhibitor Pitstop 2, adding 
30 μM Pitstop 2 (Abcam Biochemicals) to the BM cells for 15 minutes 
at 37°C and then washing it out immediately prior to cells being incu-
bated with rmDEK. To examine whether DEK functions different-
ly in actively cycling cells, BM cells were incubated with 100 μg/ml 
hydroxyurea (Sigma-Aldrich, catalog H8627) for 45 minutes at 37°C 
and then washed twice immediately prior to use in experiments. Alter-
natively, high-specific-activity 3HTdr kill assays were performed as 
previously described (23). Briefly, BM cells were treated with 50 μCi 
high-specific-activity 3HTdr (20 Ci/mmol; DuPont NEN) at 37°C for 
20 minutes or at room temperature for 40 minutes, then washed twice 
immediately prior to use in experiments.
Pretreatment of DEK with DEK-targeting aptamers. Anti-DEK 
aptamers were generated using SELEX technology as previously 
reported (8), and 2 single-stranded DNA aptamers with high affini-
ty for rDEK proteins were selected: DTA-64 and DTA-85+ends. The 
library of single-stranded DNAs originally screened to obtain the 
DEK-targeted aptamers was used as a control. Recombinant DEK was 
pretreated with 100 ng/ml DTA-64, DTA-85+ends, aptamer library, or 
vehicle control for 1 hour at 37°C.
length form, but also that of the other. In addition, alterations to 
DEK expression levels in patient plasma samples in some cancers 
(e.g., head and neck squamous cell carcinoma) correlate with 
poor disease outcome (37). Thus, it might be interesting to exam-
ine in the future extracellular DEK concentrations in MDS/AML 
patients to determine whether changes to DEK concentrations in 
the plasma correlate with disease progression/outcome.
Methods
Production of recombinant DEK. rmDEK and rhDEK were purified from 
insect cells as described previously (13, 38). Three days after infection 
with a high-titer virus stock, HighFive cells (Invitrogen) were harvest-
ed and washed 3 times with PBS prior to lysis with 2 ml lysis buffer per 
175-cm2 flask (100 mM Tris-Cl [pH 7.5], 150 mM NaCl, 5 mM MgCl2, 
1% NP-40, 5 mM imidazole). The lysate was further treated with 1.3 M 
NaCl for 20 minutes at room temperature, cleared (100,000 g, 10 
minutes), and diluted with lysis buffer to a final concentration of 700 
mM NaCl. After incubation for 1 hour at 4°C with Ni-nitrilotriacetic 
acid–agarose beads (QIAGEN), the beads were washed 3 times with 
10 volumes of buffer 1 (50 mM Tris-Cl [pH 7.5], 150 mM NaCl, 50 
mM imidazole), 3 times with 10 volumes of buffer 2 (50 mM Tris-Cl 
[pH 7.5], 300 mM NaCl, and 50 mM imidazole), and again with 10 
volumes of buffer 1. Elution was performed with 50 mM Tris-Cl (pH 
7.5)/150 mM NaCl/500 mM imidazole. All recombinant proteins were 
dialyzed prior to being aliquoted and then stored at –80°C. Mutant 
DEK proteins were made as previously described (13, 38–41). See Sup-
plemental Methods for further information.
Mice. Male and female C57BL/6J, Boy/J, B6×Boy/J F1 (here-
in referred to as F1), and immunodeficient NSG (NOD.Cg-Prkdcscid 
IL2rgtm1Wjl/SzJ) mice (8–10 weeks old) were obtained from an on-site 
breeding core facility at Indiana University School of Medicine. Male 
and female 8- to 10-week-old B6.129S2(C)-Cxcr2tm1Mwm/J homozy-
gous (herein referred to as Cxcr2–/–) and WT littermate control mice 
were bred for us by the Jackson Laboratory in a gnotobiotic facility. 
Male and female C57BL/6/129/SvEv (herein referred to as Dek–/–) 
mice were obtained from Gerard Grosveld, St. Jude Children’s Hos-
pital, Memphis, Tennessee, USA, and were adapted at the University 
of Michigan to a C57BL/6 background by back-breeding the homo-
zygous knockout mouse with WT C57BL/6 mice for 9 generations 
(8, 13, 42). Dek–/– and littermate control mice were initially housed at 
the Animal Maintenance Facility at the University of Michigan Med-
ical Center and then transferred to the Indiana University School of 
Medicine animal facility at 10–13 weeks of age. Animals were main-
tained under temperature- and light-controlled conditions (21–24°C, 
12-hour light/12-hour dark cycle) and were group-housed according to 
age, sex, and genotype. Mice were fed ad libitum. For all experiments, 
mice were matched by age and sex. For in vivo treatment with rmDEK, 
WT, Dek–/–, and Cxcr2–/– mice were injected with 10 μg dialyzed WT 
rmDEK, drmDEK, rhNLS-DEK, rhDBM-DEK, or vehicle control s.c. 
once a day for 2 days. BM was then collected at the indicated time 
points (24, 48, 72, 96, or 144 hours after final injection) and analyzed.
Isolation of mouse Lin– BM cells and human CD34+ umbilical CB cells. 
Mouse BM was isolated from the femur of the indicated mouse strain 
immediately prior to use by flushing either in PBS (for transplantation 
studies; Lonza) or in Iscove’s Modified Dulbecco’s Medium (IMDM; 
Lonza) with HEPES, l-glutamine, and 10% FBS (Fisher Scientific) 
for all culture experiments. Lineage depletion of mouse BM was per-
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PE-CF594–anti-CD45RA (clone HI100; BD Biosciences), PE-Cy7–
anti-CD90 (clone 5E10; BD Biosciences), PerCP-Cy5.5–anti-CD49f 
(clone GoH3; BD Biosciences), and APC–anti-CD45 (clone HI30; BD 
Biosciences). HSC and HPC populations for mice were defined as fol-
lows — LSK cells: Lin–Sca-1+c-Kit+; LT-HSCs: LSK Flt3–CD34– or LSK 
Flt3–CD34–CD150+CD48–CD41–; ST-HSCs: LSK Flt3–CD34+; MPPs: 
LSK Flt3+CD34+. HSCs in human CB were defined as Lin–CD34+CD38–
CD45RA–CD90+CD49f+ (43). For analysis of transplantation experi-
ments, APC–anti-CD45.2 (clone 104) and FITC–anti-CD45.1 (clone 
A20) were purchased from BD Biosciences. For all antibodies used in 
these studies, the validation for the relevant species and applications 
can be found on the indicated manufacturer’s website.
RNA-Seq library preparation and analysis. BM from Dek–/– mice was 
cultured in RPMI-1640 media (Lonza) with 10% FBS (Fisher Scien-
tific) for 16 hours with 50 nM rmDEK or vehicle control. The AllPrep 
DNA/RNA Mini Kit (QIAGEN) was utilized to isolate RNA from cell 
lysates. RNase-Free DNase (QIAGEN) was used to eliminate contam-
inating genomic DNA. RNA integrity was evaluated using an Agilent 
TapeStation. Strand-specific libraries for 3 replicate pairs of DEK- and 
vehicle-treated samples were prepared using the TruSeq Stranded 
mRNA kit (Illumina) according to the manufacturer’s protocol. Library 
preparations were done in conjunction with the University of Michigan 
Sequencing Core. Single-end, strand-specific libraries were sequenced 
with an Illumina HiSeq 4000 (50-nucleotide read length). Sequencing 
results were run through a computational pipeline to trim (Trim Galore; 
https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) 
low-quality bases and adapters, align reads (STAR; https://code. 
google.com/archive/p/rna-star/) to the mouse reference genome 
(UCSC mm10 from iGenomes; Illumina), assemble aligned reads 
(HTseq) (44), and call differentially expressed genes (using the quasi- 
likelihood method with a paired design in edgeR) (45). An absolute fold 
change (FC) >1.5 and FDR <0.05 were required in order for a gene to 
be considered differentially expressed. Pathway analysis to identify 
enriched Gene Ontology (GO) terms was conducted using RNA-Enrich 
(46). The data discussed in this publication have been deposited in the 
NCBI’s Gene Expression Omnibus (GEO GSE126875).
Intracellular phosphoprotein staining. Mouse Lin– BM cells were 
left unstimulated or stimulated with 100 ng/ml rmSCF (R&D Sys-
tems), 100 ng/ml rhSDF1α (also known as CXCL12; R&D Systems, 
catalog 350-NS), 100 ng/ml rhIL-8 (R&D Systems), 50 nM rmDEK, 
50 nM GST WT rhDEK, 50 nM GST rhDBM-DEK, or 50 nM GST 
rhNLS-DEK for 15 minutes, 30 minutes, 60 minutes, or 16 hours at 
37°C. Cells were put on ice, stained for surface markers, fixed with BD 
Cytofix Buffer (BD Biosciences) for 10 minutes at 37°C, and then per-
meabilized with BD Phosflow Perm Buffer III (BD Biosciences) for 30 
minutes on ice. Cells were then washed twice, stained with antibody 
against the indicated phosphoprotein, and then analyzed on an LSR 
II flow cytometer. The manufacturer-recommended (BD Bioscienc-
es) concentration of antibody was used. Data analysis was performed 
using FlowJo 7.6.3 software. For intracellular phosphoprotein stain-
ing, the following antibodies were used: PE–anti–ERK1/2 pT202/
p204 (clone 20A; BD Biosciences), PE–anti–AKT pS473 (clone M89-
61; BD Biosciences), and PE–anti–p38 MAPK pT180/pY182 (clone 36/
p38 pT180/pY182; BD Biosciences).
HSC expansion assays. For expansion of human HSCs, CD34+ CB 
cells were isolated as described above, then cultured at 50,000 cells/
well in RPMI-1640 media (Lonza) with 10% FBS (Fisher Scientific), 
DPP4 truncation of rmDEK and rhCXCL8. Soluble human and por-
cine DPP4, prepared from human placental tissue or porcine kidney, 
were purchased from MP Biomedicals or Sigma-Aldrich (no. D7052), 
respectively, and used at approximately 0.25 μg for every 1 μg of full-
length rmDEK or rhIL-8 (also known as CXCL8; R&D Systems, cat-
alog 208-IL) protein per digestion at 37°C for at least 18 hours. Prior 
to use, truncated protein was treated with 5 nM of the DPP4 inhibitor 
diprotin A (Enzo Life Science, catalog ALX-260-036) for 30 minutes 
at room temperature.
HPC assays. For HPC assays performed in agar, BM cells flushed 
from the femurs of the indicated mouse strain were plated at 5 × 104 
cells/ml in 0.3% semisolid agar medium and IMDM (Lonza) with 10% 
FBS (Fisher Scientific) that did or did not contain 10 ng/ml rmGM-CSF 
(R&D Systems, catalog 415-ML), 50 ng/ml rmSCF (R&D Systems, cat-
alog 455-MC), 0.1–50 nM rmDEK, 0.1–50 nM GST rhDEK, 0.1–50 nM 
GST rhDBM-DEK, 0.1–50 nM GST rhNLS-DEK, 0.1–100 ng/ml rhIL-8 
(R&D Systems), 0.1–100 ng/ml rmMIP2 (also known as CXCL2; R&D 
Systems, catalog 452-M2), 100 ng/ml rmMIP1α (CCL3; R&D Systems, 
catalog 450-MA), and/or 100 ng/ml rm6Ckine (CCL21; R&D Sys-
tems, catalog 457-6C), as indicated. Colonies were scored after 6 days 
of incubation at 5% CO2 and lowered, 5% O2 in a humidified chamber. 
For HPC assays performed in methylcellulose, BM cells flushed from 
the femurs of the indicated mouse strain were plated at 5 × 104 cells/
ml in 1% methylcellulose culture medium with 0.1 mM hemin (Sigma- 
Aldrich), 30% FBS, 1 U/ml recombinant human erythropoietin (rhEPO; 
Amgen), 50 ng/ml rmSCF, and 5% vol/vol pokeweed mitogen mouse 
spleen cell conditioned medium. Colonies were scored after 6 days of 
incubation at 5% CO2 and lowered, 5% O2 in a humidified chamber, and 
CFU-GM, BFU-E, and CFU-GEMM progenitors were distinguished 
by examining the morphology of the colonies. Where indicated, total 
number of colonies per femur was calculated (23).
Flow cytometry. For analyzing HSC and HPC phenotypes in 
mouse BM and human CB, cells were collected at a concentration of 
approximately 2 × 106 cells per tube, washed in PBS, incubated in flu-
orescently conjugated anti-mouse or -human antibody cocktail for 20 
minutes at room temperature, washed in PBS, and then fixed in 1% 
formaldehyde. The samples were analyzed on an LSR II flow cytom-
eter (BD Biosciences). One microgram of antibody was used per one 
million cells. Single-color compensation and isotype controls were 
included for each experiment. Data analysis was performed using 
FlowJo 7.6.3 software (Tree Star). Gates were determined using flu-
orescence minus one controls. The percent of each population was 
used to calculate the absolute number of each population per femur 
— for mouse phenotyping markers: FITC- or Pacific Blue–mouse lin-
eage cocktail (CD3, Gr-1, CD11b, CD45R, Ter119; BioLegend, catalog 
133302 and 133310), PE-CF594–anti-Ly6A/E (also known as Sca-1; 
clone D7; BD Biosciences), APC-H7–anti-CD117 (c-Kit; clone 2B8; BD 
Biosciences), APC– or PE–anti-CD135 (Flt3; clone A2F10.1; BD Bio-
sciences), PE– or BV421–anti-CD34 (clone RAM34; BD Biosciences), 
PerCP-Cy5.5–anti-CD16/CD32 (FcγR; clone 2.4G2; BD Biosciences), 
PE– or BV421–anti-CD150 (clone Q38-480; BD Biosciences), FITC– 
or BV421–anti-CD48 (clone HM48-1; BD Biosciences), FITC– or 
BV421–anti-CD41 (clone MWReg30; BD Biosciences), FITC–anti-
CD45.1 (clone A20; BD Biosciences), APC–anti-CD45.2 (clone 104; 
BD Biosciences), and APC–anti-CD184 (clone 2B11/CXCR4; BD Bio-
sciences); for human phenotyping markers: FITC–anti-CD34 (clone 
581; BD Biosciences), PE–anti-CD38 (clone HIT2; BD Biosciences), 
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the progeny of the equivalent number of cells) were injected into NSG 
mice that had been sublethally irradiated (350 cGy) 24 hours before 
transplantation. Following 2 and 4 months, the percentage of donor 
human CD45+ cells in the PB and BM (month 4 only) was determined 
by flow cytometry. The number of mice with greater than 1% human 
donor-derived BM cells was determined for each dose. The HSC fre-
quency was calculated using L-Calc software and plotted using ELDA 
software. For secondary transplants, 2 × 106 BM cells from the above 
primary recipient mice were intravenously injected into sublethally 
irradiated NSG mice. The percentage of human CD45+ cells in the PB 
and BM (month 4 only) was evaluated.
ImageStream analysis of H3K9 trimethylation. Lin– BM cells from 
Dek–/– and littermate WT control mice were stained for the indicated 
surface markers, then fixed/permeabilized using BD Cytofix/Cyto-
perm Fixation/Permeabilization Kit (BD Biosciences) according to the 
manufacturer’s instructions. Cells were then incubated with a 1:200 
dilution of anti–trimethyl histone H3 (Lys9) Alexa Flour 488 antibody 
(EMD Millipore Corporation, catalog 07-442-AF488) for 30 minutes 
at 4°C in the dark. Following staining, cells were washed and refixed 
using BD Cytofix buffer for 10 minutes. Cells were then washed, resus-
pended in 20 μM DRAQ5 (BD Biosciences, catalog 564903), incubat-
ed for 10 minutes at room temperature, and then analyzed. 50,000–
80,000 Lin–, c-Kit+ events were collected using the slow stream setting 
at a ×40 objective for all samples on an ImageStreamX MKII (Amnis/
EMD Millipore) using INSPIRE ImageStreamX MKII Software and 
analyzed using IDEAS Image Data Exploration and Analysis Software 
version 4 (Amnis/EMD Millipore). Spectral compensation was digital-
ly performed on a pixel-by-pixel basis prior to data analysis. Cells that 
were in focus when imaged, then single, live cells were gated based 
on their aspect ratio and area of the bright-field image. Samples were 
then gated on the LSK population, and the relationship between the 
H3K9me3 and DRAQ5 staining was measured using the “similari-
ty” feature in the IDEAS software. The similarity score, which is the 
log-transformed Pearson’s correlation coefficient between the pixel 
values of 2 image pairs, provided a measure of the degree of nuclear 
staining of H3K9me3 by comparing H3K9me3 staining with DRAQ5 
staining by measuring the pixel intensity correlation between the 2 
images. Cells with high similarity scores demonstrated greater H3K9 
trimethylation in the nucleus, and cells with lower similarity scores had 
less H3K9 trimethylation in the nucleus. Gating of the similarity score 
histograms based on LSK cells from untreated littermate control BM 
was used to calculate the percent change in H3K9me3 in the nuclei of 
littermate control and Dek–/– BM cells following different treatments.
Statistics. Results are expressed as mean values ± SD or SEM as 
indicated. Two-tailed Student’s t test was used where indicated. One-
way ANOVA with post hoc Tukey’s multiple-comparisons test was 
used when comparing 3 or more groups. Poisson statistical analysis 
was used for the limiting dilution assays. A P value less than 0.05 was 
considered statistically significant.
Study approval. The Indiana University Institutional Review 
Board approved all CB studies. All animal procedures were approved 
by the University of Michigan and Indiana University Committees on 
Use and Care of Animals.
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100 ng/ml rhSCF (R&D Systems, catalog 7466-SC-010/CF), 100 
ng/ml rhTPO (R&D Systems, catalog 288-TP-200/CF), 100 ng/ml 
rhFlt3L (BioLegend, catalog 710802), and either 50 nM rhDEK or 
vehicle control at 37°C at 5% CO2 and lowered, 5% O2 in a humidified 
chamber. Cells were removed after 4 days and counted. Flow cytome-
try was then performed, examining HSC frequency in culture at time 
of input and at 4 days of culture. The percent HSCs and number of cells 
per well were then used to calculate HSC expansion. For expansion of 
mouse LT-HSCs, Lin– BM cells were isolated as described above, then 
cultured at 50,000 cells/well in RPMI-1640 media (Lonza) with 10% 
FBS (Fisher Scientific), 100 ng/ml rmSCF (R&D Systems, catalog 
455-MC-010), 100 ng/ml rmTPO (R&D Systems, catalog 488-TO-
055/CF), 100 ng/ml rmFlt3L (BioLegend, catalog 550706), and 50 
nM rmDEK, 50 nM GST rhDEK, 50 nM GST rhNLS-DEK, 50 nM GST 
rhDBM-DEK, or vehicle control at 37°C at 5% CO2 and lowered, 5% 
O2 in a humidified chamber. The mouse LT-HSC expansion assay was 
then performed similarly to the human assay.
HSC and HPC engrafting studies. To analyze the effect of rmDEK 
treatment in vivo, C57BL/6 mice were injected with 10 μg dialyzed WT 
rmDEK, drmDEK, or vehicle control s.c. once a day for 2 days. BM was 
then collected 24 or 48 hours after final injection. Competitive trans-
plantations were performed using donor BM cells from vehicle- or 
rmDEK-treated C57BL/6 mice (CD45.1–CD45.2+). These cells were 
mixed at a 1:1 ratio (1 × 105 cells) with competitor BM from Boy/J mice 
(CD45.1+CD45.2–) and injected intravenously into B6×Boy/J F1 mice 
(CD45.1+CD45.2+) that had been lethally irradiated (950 cGy) 24 hours 
prior to transplantation. Following 1, 2, 4, and 6 months, the percentage of 
donor CD45.1–CD45.2+ cells in the PB was determined by flow cytometry.
Homing studies. C57BL/6 mice (CD45.1–CD45.2+) were injected 
with 10 μg dialyzed WT rmDEK or vehicle control s.c. once a day for 2 
days. BM was then collected 24 or 48 hours after final injection. Twelve 
million cells from these mice were then injected i.v. into lethally irra-
diated (950 cGy, 24 hours prior) B6×Boy/J F1 mice (CD45.1+CD45.2+) 
hosts. Eighteen hours following injection, BM from host mice was 
collected and analyzed by flow cytometry for the presence of CD45.1–
CD45.2+ LSK CD150+, LSK, and LK cells.
Limiting dilution analysis. For mouse studies, progeny cells from 
C57BL/6 (CD45.1–CD45.2+) mouse Lin– BM HSC ex vivo expansion 
assays were utilized. Increasing doses of uncultured or 4-day-cul-
tured vehicle- or rmDEK-treated mouse Lin– cells (10,000, 25,000, 
or 100,000 cells or the progeny of the equivalent number of cells) 
were mixed with 1 × 105 BoyJ (CD45.1+CD45.2–) BM competitor cells, 
then intravenously injected into F1 mice (CD45.1+CD45.2+) that had 
been lethally irradiated (950 cGy) 24 hours before transplantation. 
Following 2 and 4 months, the percentage of donor CD45.1–CD45.2+ 
cells in the PB and BM (month 4 only) was determined by flow cytom-
etry. The number of mice with greater than 15% donor-derived BM 
cells (CD45.1–CD45.2+) was determined for each dose. The HSC fre-
quency was calculated using L-Calc software (STEMCELL Technol-
ogies) and plotted using ELDA software (http://bioinf.wehi.edu.au/
software/elda/). For secondary transplants, 2 × 106 BM cells from the 
above primary recipient mice were intravenously injected into lethally 
irradiated F1 mice. The percentage of CD45.1–CD45.2+ cells in the PB 
and BM (month 4 only) was evaluated. For human studies, the prog-
eny cells from human CD34+ CB HSC ex vivo expansion assays were 
utilized. Increasing doses of uncultured or 4-day-cultured vehicle- or 
rhDEK-treated human CD34+ CB cells (500, 2500, or 10,000 cells or 
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